Biocon Limited - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Biocon Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Biocon Limited - Product Pipeline Review - 2014', provides an overview of the Biocon Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biocon Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biocon Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biocon Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Biocon Limited's pipeline products

Reasons to buy

- Evaluate Biocon Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biocon Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biocon Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biocon Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biocon Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biocon Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Biocon Limited Snapshot 6
Biocon Limited Overview 6
Key Information 6
Key Facts 6
Biocon Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Biocon Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Biocon Limited - Pipeline Products Glance 15
Biocon Limited - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Biocon Limited - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Biocon Limited - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Biocon Limited - Drug Profiles 19
(rosuvastatin calcium + ezetimibe) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
(rosuvastatin calcium + olmesartan medoxomil) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
trastuzumab biosimilar 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
insulin human 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
itolizumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
nimotuzumab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BVX-20 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
insulin glargine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
adalimumab biosimilar 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
bevacizumab biosimilar 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
etanercept biosimilar 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
insulin aspart 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
insulin lispro 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
pegfilgrastim biosimilar 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Biocon Limited - Pipeline Analysis 37
Biocon Limited - Pipeline Products by Target 37
Biocon Limited - Pipeline Products by Route of Administration 39
Biocon Limited - Pipeline Products by Molecule Type 40
Biocon Limited - Pipeline Products by Mechanism of Action 41
Biocon Limited - Recent Pipeline Updates 43
Biocon Limited - Dormant Projects 47
Biocon Limited - Company Statement 48
Biocon Limited - Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Biocon Limited, Key Information 6
Biocon Limited, Key Facts 6
Biocon Limited - Pipeline by Indication, 2014 8
Biocon Limited - Pipeline by Stage of Development, 2014 10
Biocon Limited - Monotherapy Products in Pipeline, 2014 11
Biocon Limited - Combination Treatment Modalities in Pipeline, 2014 12
Biocon Limited - Partnered Products in Pipeline, 2014 13
Biocon Limited - Partnered Products/ Combination Treatment Modalities, 2014 14
Biocon Limited - Phase III, 2014 15
Biocon Limited - Phase II, 2014 16
Biocon Limited - Phase I, 2014 17
Biocon Limited - Preclinical, 2014 18
Biocon Limited - Pipeline by Target, 2014 38
Biocon Limited - Pipeline by Route of Administration, 2014 39
Biocon Limited - Pipeline by Molecule Type, 2014 40
Biocon Limited - Pipeline Products by Mechanism of Action, 2014 42
Biocon Limited - Recent Pipeline Updates, 2014 43
Biocon Limited - Dormant Developmental Projects,2014 47
Biocon Limited, Other Locations 49
Biocon Limited, Subsidiaries 50